| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
40,365 |
37,275 |
$1.73M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,537 |
18,148 |
$551K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,738 |
1,652 |
$415K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
5,224 |
4,910 |
$363K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
12,542 |
11,257 |
$246K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,675 |
4,398 |
$231K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12,340 |
11,520 |
$219K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,793 |
5,212 |
$72K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,844 |
6,417 |
$69K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,713 |
1,631 |
$35K |
| 87581 |
|
1,717 |
1,631 |
$35K |
| 87486 |
|
1,709 |
1,628 |
$35K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,034 |
998 |
$23K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
725 |
700 |
$23K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
631 |
556 |
$17K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
214 |
208 |
$13K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
350 |
337 |
$8K |
| 71046 |
Radiologic examination, chest; 2 views |
442 |
421 |
$7K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
415 |
398 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,431 |
3,107 |
$5K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
106 |
97 |
$4K |
| 87807 |
|
184 |
178 |
$2K |
| 87428 |
|
76 |
64 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
53 |
48 |
$1K |
| 90686 |
|
54 |
53 |
$916.17 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
62 |
59 |
$671.04 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
192 |
166 |
$620.59 |
| 81002 |
|
1,945 |
1,832 |
$587.38 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
31 |
25 |
$149.90 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
28 |
24 |
$4.68 |